Insights | Fish & Richardson

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Legal Project Management

Knowledge Management

Legal Technology Services

Patent Litigation

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Standard Essential Patents

Chancery & Corporate Governance

<p><em>Inter Partes </em>Review</p>

Post-Grant Review

<p><em>Ex Parte</em> Reexamination</p>

Supplemental Examination

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Electrical & Computer Technology

Software & Internet

Consumer Electronics

Artificial Intelligence

Digital Media & E-Commerce

Financial, Business & FinTech Services

Telecommunications

Energy & Chemicals

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Autonomous Vehicles

Thought Leadership

IP Law Essentials

Post-Grant Annual Reports

Search results

Blog | April 18, 2025

Trump’s Drug Price Executive Order: What Drugmakers Should Know

Webinar | January 22, 2025

Hatch-Waxman 2024 Year in Review

Blog | January 08, 2025

Hatch-Waxman 201

Article | November 20, 2024

How a Second Trump Presidency Could Shape IP

Webinar | September 12, 2024

Hatch-Waxman 201

Article | February 05, 2024

Hatch-Waxman 2023 Year in Review

Blog | December 18, 2023

The Federal Circuit Weighs in On Hatch-Waxman “Skinny” Label Infringement Dispute

Webinar | December 07, 2023

Hatch-Waxman 2023 Year in Review

Blog | November 09, 2023

FTC Challenges More Than 100 Patents as Improperly Listed in Orange Book

Blog | September 25, 2023

Federal Circuit Evaluates Enablement for Antibody Claims for the First Time Since Amgen v. Sanofi in Baxalta Inc. et al. v. Genentech, Inc.

Webinar | January 04, 2023

Hatch-Waxman 2022 Year in Review

Blog | October 11, 2022

Federal Circuit Affirms PTAB's Final Written Decision that Merck's Claimed Inventions Were Not "At Once Envisaged" From the Prior Art